Questions asked in the House of Commons on the treatment of ultra orphan diseases
Ian Liddell-Grainger (Conservative MP for Bridgwater and West Somerset) asked questions in the House of Commons in relation to the treatment of ultra orphan diseases.
12/07 – House of Commons – Written Answer: NHS: Drugs
Ian Liddell-Grainger (Conservative, Bridgwater and West Somerset): To ask the Secretary of State for Health what plans he has for the future appraisal of drugs for the treatment of ultra orphan diseases.
Simon Burns (Minister of State for Health): In the great majority of cases the National Institute for Health and Clinical Excellence (NICE) will continue to appraise important new drugs. However, for a small number of drugs for very small patient populations, where it is not appropriate for NICE to carry out an appraisal, it may be more appropriate for a drug to be considered by the Advisory Group for National Specialised Services as part of the arrangements for national specialised commissioning.
13/07 – House of Commons – Written Answers
Ian Liddell-Grainger (Conservative, Bridgwater and West Somerset): To ask the Secretary of State for Health what the remit is of the Advisory Group for National Specialised Services.
Simon Burns (Minister of State for Health): The role of the Advisory Group for National Specialised Services will be to advise on:
- which services and technologies should be nationally commissioned;
- which centres should provide them;
- the annual budget for nationally commissioned services and technologies; and
- the high level strategy for nationally commissioned services and technologies.
Liddell-Grainger (Conservative, Bridgwater and West Somerset): To ask the Secretary of State for Health what plans his Department has to implement the provisions of the Council Recommendation for a European Action on rare diseases.
Anne Milton (Parliamentary Under-Secretary for Health): The Department is working with the Devolved Administrations and key interest groups to develop a plan for rare disease by 2013 in line with the Council’s recommendation.